Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Trial Profile

Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Forodesine (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Mundipharma International
  • Most Recent Events

    • 12 Dec 2017 Results of the final data analysis, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
    • 09 May 2017 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top